BACKGROUND AND PURPOSE: Although various particulate materials have been developed as embolization agents, their biocompatibility remains unclear. We used an animal model to examine the possibility of using FDA-approved microcrystalline cellulose spheres (CELPHERE) as solid embolic material for the permanent occlusion of blood vessels. METHODS: Angiographic and histologic studies in 12 canine renal arterial systems were conducted to evaluate the performance of CELPHERE beads at 1 hour, and at 4 and 12 weeks after embolization. RESULTS: The CELPHERE beads traveled to vessels with diameters approximating their own. Larger vessels were occluded by aggregations of beads. There was no disruption of vessel walls and no evidence of perivascular hemorrhage or inflammatory changes. CONCLUSION: Because CELPHERE beads are easy to handle, highly biocompatible, and have few adverse effects, they are suitable for intravascular applications.
BACKGROUND AND PURPOSE: Although various particulate materials have been developed as embolization agents, their biocompatibility remains unclear. We used an animal model to examine the possibility of using FDA-approved microcrystalline cellulose spheres (CELPHERE) as solid embolic material for the permanent occlusion of blood vessels. METHODS: Angiographic and histologic studies in 12 canine renal arterial systems were conducted to evaluate the performance of CELPHERE beads at 1 hour, and at 4 and 12 weeks after embolization. RESULTS: The CELPHERE beads traveled to vessels with diameters approximating their own. Larger vessels were occluded by aggregations of beads. There was no disruption of vessel walls and no evidence of perivascular hemorrhage or inflammatory changes. CONCLUSION: Because CELPHERE beads are easy to handle, highly biocompatible, and have few adverse effects, they are suitable for intravascular applications.
Authors: D Horák; F Svec; J Kálal; K Gumargalieva; A Adamyan; N Skuba; M Titova; N Trostenyuk Journal: Biomaterials Date: 1986-05 Impact factor: 12.479
Authors: R Beaujeux; A Laurent; M Wassef; A Casasco; Y P Gobin; A Aymard; D Rüfenacht; J J Merland Journal: AJNR Am J Neuroradiol Date: 1996-03 Impact factor: 3.825
Authors: A K Wakhloo; F D Juengling; V Van Velthoven; M Schumacher; J Hennig; K Schwechheimer Journal: AJNR Am J Neuroradiol Date: 1993 May-Jun Impact factor: 3.825
Authors: H Zhao; C Zheng; G Feng; Y Zhao; H Liang; H Wu; G Zhou; B Liang; Y Wang; X Xia Journal: AJNR Am J Neuroradiol Date: 2012-08-02 Impact factor: 3.825
Authors: Nikolett Kállai-Szabó; Miléna Lengyel; Dóra Farkas; Ádám Tibor Barna; Christian Fleck; Bálint Basa; István Antal Journal: Pharmaceutics Date: 2022-06-18 Impact factor: 6.525